RANI

Rani Therapeutics Holdings, Inc. (RANI) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Rani Therapeutics is a clinical-stage biotherapeutics company developing the RaniPill, a drug-agnostic oral delivery platform designed to administer biologics and drugs orally. The company operates in one segment and is classified as an emerging growth company and a smaller reporting company. As of the filing date, the company has no approved commercial products and relies on collaboration revenue and financing to fund operations.

Key Financial Metrics

Debt & Liabilities: The company reported no long-term debt as of March 31, 2026. Total liabilities were $16.3 million, primarily consisting of deferred revenue ($6.8 million) and operating lease liabilities ($3.9 million).

Material Changes vs. Prior Period

• Revenue Growth: Contract revenue increased 893% to $1.7 million, driven by the recognition of revenue from the Chugai Collaboration and License Agreement signed in October 2025.
• Expense Reduction: Total operating expenses decreased 17.5% to $10.0 million. Research and Development (R&D) expenses fell 21.4% to $5.2 million, and General and Administrative (G&A) expenses fell 13.0% to $4.9 million, primarily due to lower compensation costs.
• Improved Loss Profile: Net loss decreased 37.1% to $8.0 million, while net loss attributable to Rani decreased slightly by 3.2% to $7.0 million.
• Interest Expense: Interest expense and other, net, decreased significantly by 90.7% to $0.1 million, reflecting the repayment of prior debt obligations.

Guidance, Outlook, and Risks

Outlook & Liquidity: Management expects cash, cash equivalents, and marketable securities of $43.4 million to be sufficient to fund operations for at least twelve months from the filing date. The company anticipates continuing to incur operating losses as it advances clinical trials and develops the RaniPill platform.

Clinical Progress: In December 2025, the company initiated a Phase 1 clinical trial for RT-114 (a GLP-1/GLP-2 agonist) in collaboration with ProGen. The trial is ongoing in Australia, with updates expected in 2027.

Key Risks & Contingencies:

• Nasdaq Delisting Risk: On May 11, 2026, the company received a deficiency notice from Nasdaq because its Class A common stock closed below $1.00 per share for 30 consecutive trading days. The company has 180 days (until November 9, 2026) to regain compliance or risk delisting.
• Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of March 31, 2026, due to a previously identified material weakness regarding the accounting for complex transactions. Remediation efforts are ongoing.
• Capital Needs: The company will require substantial additional capital to complete development and commercialization. Future funding may come from equity offerings, debt, or collaborations, which may not be available on favorable terms.

Investor Verification Checklist

• Stock Price Compliance: Verify the current trading price of RANI to assess the likelihood of regaining Nasdaq compliance within the 180-day window.
• Chugai Milestone Recognition: Review the specific terms of the Chugai Collaboration Agreement to understand the timeline for recognizing the remaining $10.0 million upfront payment and potential future milestones.
• Remediation of Material Weakness: Monitor future filings for updates on the remediation of the internal control material weakness to ensure financial reporting reliability.
• Cash Burn Rate: Track quarterly operating cash flow to confirm the "12-month runway" assertion remains valid given ongoing R&D expenditures.
• Warrant Activity: Note the significant number of outstanding warrants (approx. 131.6 million) which could impact future dilution if exercised.